Takeda, Millennium merger clears waiting period hurdle

By Lisa Kerner

Charlotte, N.C., April 29 - The Federal Trade Commission granted early termination of the Hart-Scott-Rodino waiting period in the proposed merger of Takeda Pharmaceutical Co. Ltd. and Millennium Pharmaceuticals, Inc., the companies announced on Tuesday.

In addition, Takeda has received antitrust clearance from the Austrian Federal Competition Authority and the German Federal Cartel Office.

Takeda announced it agreed to acquire Millennium for some $8.8 billion and began a $25-per-share tender offer for the company on April 11.

The offer will end at midnight ET on May 8 unless extended, it was previously reported.

Millennium is a biopharmaceutical company located in Cambridge, Mass.

Takeda is a research-based pharmaceutical company located in Osaka, Japan.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.